Healthcare Sales & Marketing Network News: gastrointestinal bleeding

Searching News Database: gastrointestinal bleeding

HSMN NewsFeed - 25 Sep 2024
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF(R) Vial Access Needle ("VAN")
Devices Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 26 Mar 2024
Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS(R)
Biopharmaceuticals Generics Product Launch

HSMN NewsFeed - 1 Jul 2021
Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF(TM) for the Management of Postoperative Pain for up to 72 Hours
Biopharmaceuticals Drug Delivery Product Launch

HSMN NewsFeed - 13 May 2021
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF(TM) (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
Biopharmaceuticals FDA

HSMN NewsFeed - 7 May 2021
Perosphere Technologies Announces CE-IVD Marking of the Perosphere Technologies PoC Coagulometer System for DOAC and Heparin Testing
Devices Diagnostics Regulatory

HSMN NewsFeed - 5 Mar 2020
New Data Demonstrates Andexxa(R) Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 May 2019
U.S. FDA Approves GATTEX(R) (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 28 Jan 2019
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Aug 2018
AbbVie Announces IMBRUVICA(R) (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Jun 2018
IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 May 2018
Egalet Announces Large Regional Plan to Cover SPRIX(R) Nasal Spray
Biopharmaceuticals Reimbursement

HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Feb 2017
FDA Approves Amgen's Parsabiv(TM) (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Jan 2017
Apollo Endosurgery Appoints Dr. Christopher J. Gostout as Chief Medical Officer
Devices Surgery Personnel

HSMN NewsFeed - 26 Sep 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 30 Aug 2016
Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXXA-4(TM) Study of Factor Xa Inhibitor Antidote AndexXa(TM) (andexanet alfa) in Patients with Acute Major Bleeding
Biopharmaceuticals

HSMN NewsFeed - 29 Jun 2016
AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA(R)) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options
Biopharmaceuticals

HSMN NewsFeed - 9 May 2016
U.S. FDA Expands IMBRUVICA(R) (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Feb 2016
VIVLODEX(TM) Now Available in U.S. Pharmacies for the Management of Osteoarthritis Pain
Biopharmaceuticals Product Launch

HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Oct 2015
Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX(TM) - First Low Dose SoluMatrix(R) Meloxicam for Osteoarthritis Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 18 May 2015
Actavis Launches NAMZARIC(TM) (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease
Biopharmaceuticals Neurology Product Launch

HSMN NewsFeed - 27 Oct 2014
First Ever Five-Millimeter Laparoscopic Stapled Small Bowel Anastomosis Performed With Cardica's MicroCutter XCHANGE(R) 30
Devices Surgery

HSMN NewsFeed - 26 Feb 2014
Quest Diagnostics Expands Hereditary Cancer Screening Offering with Lynch Syndrome Blood and Biopsy Testing for Colorectal Cancer
Diagnostics Oncology Product Launch

HSMN NewsFeed - 15 Oct 2013
Given Imaging Announces New Data That Suggests Increased Role for PillCam(R) SB in Guiding Therapy for Patients With Gastrointestinal Bleeding
Devices Gastroenterology

HSMN NewsFeed - 15 Oct 2013
Given Imaging Announces New Studies That Affirm PillCam SB as the Gold Standard for Detecting and Diagnosing Small Bowel Diseases
Devices Gastroenterology

HSMN NewsFeed - 13 Aug 2013
Covidien Introduces New Barrx(TM) RF Ablation Catheter for Treating Barrett’s Esophagus
Devices Gastroenterology Product Launch

HSMN NewsFeed - 4 Sep 2012
Higher dose of Novartis drug Exelon(R) Patch approved by FDA for patients with mild to moderate Alzheimer's disease
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Jan 2012
Given Imaging Provides Update on PillCam(R) COLON 2 Pivotal Trial Enrollment
Devices Gastroenterology

HSMN NewsFeed - 25 Oct 2011
Lilly Announces Withdrawal of Xigris(R) Following Recent Clinical Trial Results
Biopharmaceuticals

HSMN NewsFeed - 3 Jun 2011
Tarceva Nearly Doubled the Time People With a Genetically Distinct Type of Lung Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Mar 2011
Given Imaging Receives FDA Clearance for Expanded PillCam(R) SB Indications
Devices Gastroenterology FDA

HSMN NewsFeed - 3 Feb 2011
Given Imaging Announces German Public Health System to Establish PillCam(R) SB Outpatient Reimbursement Code
Devices Gastroenterology Reimbursement

HSMN NewsFeed - 26 Jan 2011
Bristol-Myers Squibb and sanofi-aventis Announce U.S. FDA Decision to Grant Pediatric Exclusivity For PLAVIX
Biopharmaceuticals Cardiology Generics FDA

HSMN NewsFeed - 5 May 2010
New Studies Presented at Digestive Disease Week Highlight the Value of PillCam(R) Capsule Endoscopy
Devices Gastroenterology

HSMN NewsFeed - 29 Apr 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received Approval in the European Union for Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 3 Mar 2010
FDA Provides 510k Clearance for BARRX Medical's HALO90 Ablation Catheter for the Treatment of Radiation Proctitis and Gastric Antral Vascular Ectasia (GAVE)
Devices Gastroenterology FDA

HSMN NewsFeed - 26 Jan 2010
Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 May 2009
FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Biopharmaceuticals FDA

HSMN NewsFeed - 20 May 2009
Given Imaging Announces One Millionth PillCam(R) Video Capsule
Devices Gastroenterology

HSMN NewsFeed - 21 Oct 2008
New Multicenter Study Underscores Value of Using PillCam(R) SB in Children Younger Than 8
Devices Gastroenterology

HSMN NewsFeed - 7 Oct 2008
Given Imaging Launches VueSpan Reading Service for PillCam(R) Video Capsules
Devices Gastroenterology

HSMN NewsFeed - 28 May 2008
Santarus Announces Development Program for New ZEGERID Prescription Product
Biopharmaceuticals

HSMN NewsFeed - 15 Apr 2008
Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Feb 2008
Quest Diagnostics to Develop Blood Test to Aid in the Detection of Colorectal Cancer
Diagnostics Oncology Licensing

HSMN NewsFeed - 19 Feb 2008
Santarus Announces Launch of ZEGERID Products by GlaxoSmithKline in Puerto Rico and U.S. Virgin Islands
Biopharmaceuticals

HSMN NewsFeed - 3 Dec 2007
Santarus Licenses Rights to GlaxoSmithKline for ZEGERID Immediate-Release Omeprazole Products in over 100 Countries
Biopharmaceuticals Distribution Licensing

HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 17 Sep 2007
Paladin and Labopharm Launch Tridural(TM) Once-Daily Tramadol Product in Canada
Biopharmaceuticals

HSMN NewsFeed - 2 Aug 2007
FDA Issues Second Approvable Letter for Trexima(TM)
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Jul 2007
Journal of Clinical Oncology Publishes Data on ZOLINZA(TM) (vorinostat), Merck's Treatment for Advanced Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Jul 2007
Labopharm and Paladin Complete Canadian Licensing and Distribution Agreement for Labopharm's Once-Daily Tramadol Product
Biopharmaceuticals Licensing Distribution

HSMN NewsFeed - 18 Jun 2007
Labopharm's Once-Daily Tramadol Approved for Sale in Canada
Biopharmaceuticals Regulatory

HSMN NewsFeed - 12 Jun 2007
Given Imaging Announces Highlights of Sixth International Conference on Capsule Endoscopy(TM)
Devices Gastroenterology

HSMN NewsFeed - 8 Jun 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
Biopharmaceuticals Neurology

HSMN NewsFeed - 2 May 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks
Biopharmaceuticals Neurology

HSMN NewsFeed - 2 May 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Provided Relief of Both Traditional and Non-traditional Migraine Symptoms
Biopharmaceuticals Neurology

HSMN NewsFeed - 20 Apr 2007
The Lancet Publishes PREVAIL Study Results Showing Lovenox(R) Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
Biopharmaceuticals

HSMN NewsFeed - 9 Nov 2006
POZEN Submits Full Response to FDA Approvable Letter For Trexima(TM)
Biopharmaceuticals FDA

HSMN NewsFeed - 2 Nov 2006
New Study Shows InSure(R) Colorectal Cancer Screening Test Significantly Better at Detecting Early Stage Colorectal Cancers Compared to Traditional Test
Diagnostics Oncology

HSMN NewsFeed - 1 Nov 2006
Given Imaging Announces New Capsule Endoscopy Reimbursement Policies for PillCam ESO and PillCam SB
Devices Gastroenterology Reimbursement

HSMN NewsFeed - 18 Oct 2006
Santarus Licenses OTC Rights to Lower Dosage Immediate-Release ZEGERID Products to Schering-Plough
Biopharmaceuticals Licensing

HSMN NewsFeed - 9 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Sep 2006
Given Imaging Announces Israel's National Health Service Will Reimburse for PillCam SB
Devices Gastroenterology Reimbursement

HSMN NewsFeed - 20 Sep 2006
New Analysis Shows Patients Who Treat Their Migraine Pain Early With Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Have Higher Sustained Pain-Free Rates Than Those Who Treat Late
Biopharmaceuticals

HSMN NewsFeed - 20 Sep 2006
New Data Show Consistent Efficacy and Tolerability of Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Across Multiple Migraine Attacks
Biopharmaceuticals

HSMN NewsFeed - 20 Sep 2006
New Data Show Peak Concentration of Sumatriptan Occurred Earlier With Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Compared to Imitrex(R) (Sumatriptan Succinate)
Biopharmaceuticals

HSMN NewsFeed - 7 Sep 2006
Quest Diagnostics Acquires Maker of InSure(R) Colorectal Cancer Screening Test
Diagnostics Mergers & Acquisitions

HSMN NewsFeed - 19 Jul 2006
Exelon(R) Patch, the first transdermal therapy for Alzheimer's disease, may provide a promising new approach to treatment
Biopharmaceuticals Neurology

HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA

Return to NewsFeed

Additional items found! 48

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 48 additional stories matching:
gastrointestinal bleeding
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!